ArticleOncotarget2017

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Mariantonietta Di Salvatore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.